Skip to main content
SpringerLink
Log in

Joint structure modification in osteoarthritis: Development of SMOAD drugs

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Primary osteoarthritis (OA) is a polygenic disease associated with age and obesity. In the OA disease setting, abnormal bone anatomy and biomechanics can set off a tissue repair response (intertwined with a mild inflammatory state) that can be seen with the imaging tools of bone scintigraphy and magnetic resonance imaging. This report focuses on weight-bearing OA (knee and hip) and looks at initiating and disease expression events in the subchondral trabecular bone. Multiple drug development targets in soft tissue (cartilage) and hard tissue (bone) can be justified. A successful structure-modifying OA drug (SMOAD) approach that preserves joint structure will likely impact both tissues. The bone and cartilage tissues may signal each other via activation of cytokine pathways and via activation of a generalized tissue repair/mild inflammation response that impacts bone and cartilage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778–799.

    Article  PubMed  CAS  Google Scholar 

  2. Osteoarthritic Disorders. Edited by Keuttner KE, Goldberg V. Rosemont, IL: American Academy of Orthopedic Surgeons; 1995:xxi-xxv.

  3. Bullough PG: Pathology of osteoarthritis. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:8.1–8.8.

    Google Scholar 

  4. Felson DT: The verdict favors nonsteroidal anti-inflammatory drugs for treatment of osteoarthritis, and a plea for more evidence on other treatments. Arthritis Rheum 2001, 44:1477–1480. Advice on how to assess the quality of clinical trials in osteoarthritis, particularly those coming from the nutriceutical or herbal medicine sectors that are not regulated by the FDA.

    Article  PubMed  CAS  Google Scholar 

  5. Bellamy N: Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthritis Cartilage 1999, 7:424–426. Perspective from one of the creators of the WOMAC instrument. A useful reference list that lists key expert consensus conferences such as OMERACT III of 1996 and OARSI 1996.

    Article  PubMed  CAS  Google Scholar 

  6. Hammad TA: Structure modification in knee osteoarthritis: methodology and outcome parameters. Osteoarthritis Cartilage 2001, 9:488–498.

    Article  PubMed  CAS  Google Scholar 

  7. US Food and Drug Administration: Guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). Rockville, MD: US FDA Center for Drug Evaluation and Research. www.fda.gov/cder/guidance/clinical. February 1998.

  8. Committee for Proprietary Medicinal Products: Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. London, UK: European Medicines Evaluation Agency (EMEA). Available on the web at www.emea.eu. July 23, 1998.

    Google Scholar 

  9. Bellamy N, Kirwan J, Boers M, et al.: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997, 24:799–802.

    PubMed  CAS  Google Scholar 

  10. Group for the Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section. Recommendations for the registration of drugs used in the treatment of Osteoarthritis. Ann Rheum Dis 1996, 55:552–557.

    Google Scholar 

  11. Altman R, Brandt K, Hochberg M, et al.: Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996, 4:217–243.

    Article  PubMed  CAS  Google Scholar 

  12. Bellamy N: WOMAC Osteoarthritis Index-User’s Guide version 3.0, 1998. Brisbane, Australia: University of Queensland; 1998. A validated instrument to measure the pain and function domains in knee and hip OA.

    Google Scholar 

  13. Lequesne M: Indices of severity and disease activity for Osteoarthritis. Semin Arthritis Rheum 1991, 20:48–54.

    Article  PubMed  CAS  Google Scholar 

  14. Buckland-Wright JC, Macfarlane DG, Lynch JA, et al.: Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation. Ann Rheum Dis 1995, 54:263–268.

    PubMed  CAS  Google Scholar 

  15. Buckland-Wright JC, Wolfe F, Ward RJ, et al.: Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999, 26:2664–2674. The relative performance and variability of various radiograph methods is provided in the paper and in references to earlier work by the same author who has played a major role in creating and validating modern radioanatomic methods for clinical trial assessment of osteoarthritis. One can rate the performance of standard x-ray, microfocal x-ray, various knee positions, and the value of adjunctive fluoroscopic positioning of the knee for longitudinal studies.

    PubMed  CAS  Google Scholar 

  16. Mazzuca SA, Brandt KD, Dieppe PA, et al.: Effect of alignment of the medial tibial plateau and x-ray beam on apparent progression of osteoarthritis in the standing anteroposterior knee radiograph. Arthritis Rheum 2001, 44:1786–1794. The importance of medial tibial plateau alignment with the central x-ray beam is emphasized, if one is to measure changes in knee joint space width over time. Only 14% of serial longitudinal x-rays showed alignment of the medial tibial plateaus in both images. It is concluded that the standard clinical standing extended knee view is unsatisfactory for clinical trial SMOAD purposes, or for accurately determining the rate at which joint space is lost as knee OA progresses.

    Article  PubMed  CAS  Google Scholar 

  17. Peterfy CG: Magnetic resonance imaging. In Osteoarthritis. Edited by Brandt KD, Doherty M, Lohmander SL. New York: Oxford University Press; 1998:473–494. Clinical investigators can expect that MRI will steadily progress and become suitable for proof of concept studies in OA as some of the issues with assessing data on joint space width and longitudinal change in cartilage volumes are successfully dealt with. This chapter appears in a 598 page authoritative book devoted to osteoarthritis that covers many topics relevant to planning and conducting clinical trials in OA.

    Google Scholar 

  18. National Institutes of Health: Public-Private Partnership Osteoarthritis Initiative; Bethesda MD. www.niams.nih.gov. July 17, 2001.

  19. Greenwald RA, Zucker S, Golub LM: Inhibition of matrix metalloproteinases: therapeutic applications. NY: NY Academy of Sciences; 1999. An excellent book of informative preclinical and clinical papers on MMP-based therapeutics.

    Google Scholar 

  20. Altman RD, Moskowitz R, and the Hyalgan Study Group: Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998, 25:2203–2212.

    PubMed  CAS  Google Scholar 

  21. Brandt KD, Smith GN, Simon LS: Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 2000, 43:1192–1203.

    Article  PubMed  CAS  Google Scholar 

  22. Pelletier JP, Yaron M, Haraoui B, et al., and the diacerein study group. Efficacy and safety of diacerein in osteoarthritis of the knee. Arthritis Rheum 2000, 43:2339–2348.

    Article  PubMed  CAS  Google Scholar 

  23. Reginster JY, Deroisy R, Rovati LC, et al.: Long term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001, 357:251–256. This study used the standing extended view of the knee, which is too variable for longitudinal studies.

    Article  PubMed  CAS  Google Scholar 

  24. National Institutes of Health: NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Bethesda, MD. www.niams.nih.gov. 2000. The GAIT study will recruit 1588 patients who will be randomized to one of five study arms: glucosamine (derived from crab shells), chondroitin (from cattle trachea), glucosamine plus chondroitin, celecoxib as active control, and placebo. The primary endpoint is symptoms and function change at 6 months. Half of the patients will be in an extended structure study using a 6∮ knee flexion x-ray, for a total of 2 years of study time.

  25. Towheed TE, Anastassiades TP: Glucosamine therapy for osteoarthritis. J Rheumatol 1999, 26:2294–2297. Examines some of the biochemistry, pharmacokinetic, and experimental design issues that need to be addressed in glucosamine OA research.

    PubMed  CAS  Google Scholar 

  26. Bigg HF, Rowan AD: The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr Opin Pharmacol 2001, 1:314–320. Penetrating and well-referenced state-of-the-art commentary on MMP as a therapeutic target in OA and RA with updates on several molecules that have been or are likely to be studied in humans.

    Article  PubMed  CAS  Google Scholar 

  27. Harris ED, Evanson JM, DiBona DR, Krane SM: Collagenase and rheumatoid arthritis. Arthritis Rheum 1970, 13:83–94.

    Article  PubMed  CAS  Google Scholar 

  28. Yu LP, Smith GN, Brandt KD, et al.: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992, 35:1150–1159.

    Article  PubMed  Google Scholar 

  29. Robinson DR: Inflammation. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:1–7.1.

    Google Scholar 

  30. Cawston TE: Tissue destruction and repair. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:7.1–8.6.

    Google Scholar 

  31. Kelley WN, Harris ED, Ruddy S, Sledge CB: Immune and inflammatory responses. In Textbook of Rheumatology. Philadelphia: WB Saunders; 1997:95–342.

    Google Scholar 

  32. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis an inflammatory disease: potential implications for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237–1247. A review that puts joint inflammation in OA into context with joint organ tissue degeneration/repair activities. The paper concludes with a commentary on futuristic OA therapies such as chondrocyte anti-apoptosis and gene therapy.

    Article  PubMed  CAS  Google Scholar 

  33. Radin EL, Rose RM: Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986, 213:34–39.

    PubMed  Google Scholar 

  34. Ding M, Odgaard A, Danielsen CC, Hvid I: Deterioration in the quality of tibial cancellous bone in early stage human osteoarthrosis. Abstract #0300. Ortho Res Soc 2001, 26:300.

    Google Scholar 

  35. Bullough PG: The geometry of diarthrodial joints, its physiologic maintenance, and the possible significance of age-related changes in geometry-to-load distribution and the development of osteoarthritis. Clin Orthop 1981, 156:61–66.

    PubMed  Google Scholar 

  36. Radin EL, Paul IL, Lowy M: A comparison of the dynamic force transmitting properties of subchondral bone and articular cartilage. J Bone Joint Surg 1970, 52:444–456.

    PubMed  CAS  Google Scholar 

  37. Hoshino A, Wallace WA: Impact absorbing properties of the human knee. J Bone Joint Surg 1987, 69:807–811.

    CAS  Google Scholar 

  38. Zysset PK, Sonny M, Hayes WC: Morphology-mechanical property relations in trabecular bone of the osteoarthritic proximal tibia. J Arthroplasty 1994, 9:203–216.

    Article  PubMed  CAS  Google Scholar 

  39. Westacott CI, Webb GR, Warnock MG, Sims JV, Elson CJ:Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum 1997, 40:1282–1291.

    PubMed  CAS  Google Scholar 

  40. Mundy GR: Bone remodeling. In Primer on the Metabolic Bone Diseases, edn 4. Philadelphia: Lippincott Williams & Wilkins; 1999:30–38. This book is published by the American Society for Bone and Mineral Research and is updated regularly. Chapters 1 through 5 provide an excellent overview of bone microanatomy and ultrastructure, molecular and cellular biology of bone, bone growth and remodeling, and bone biomechanics.

    Google Scholar 

  41. Felson DT, Chaisson CE, Hill CL, et al.: The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001, 134:541–549. Important data from MRI images and associated WOMAC algofunctional data in 401 patients that will prompt clinical investigators to look further at the role that subchondral bone plays in knee OA.

    PubMed  CAS  Google Scholar 

  42. McAlindon TE, Watt I, McCrae FM, Goddard P, Dieppe PA:Magnetic resonance imaging in osteoarthritis of the knee: correlation with radiographic and scintigraphic findings. Ann Rheum Dis 1991, 50:14–19. This and the following paper from the same group provided early evidence that imaging methods could document disease activity in subchondral bone, and in the case of bone scintigraphy, be used to predict disease progression.

    Article  PubMed  CAS  Google Scholar 

  43. Dieppe PA, Cushnaghan J, Young P, Kirwan J: Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993, 52:557–563.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arthritis Research, Department of Worldwide Clinical Development, Procter & Gamble Pharmaceuticals, 8700 Mason Montgomery Road, 45040-8006, Mason, OH, USA

    John F. Beary III MD

Authors
  1. John F. Beary III MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beary, J.F. Joint structure modification in osteoarthritis: Development of SMOAD drugs. Curr Rheumatol Rep 3, 506–512 (2001). https://doi.org/10.1007/s11926-001-0065-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-001-0065-7

Keywords

Search

Navigation